About us Contacts Drug interactions: 390 212
Drug search by name

Entrectinib and Lorbrena

Determining the interaction of Entrectinib and Lorbrena and the possibility of their joint administration.

Check result:
Entrectinib <> Lorbrena
Relevance: 22.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme. When a single 600 mg dose of entrectinib was administered with rifampin, a potent CYP450 3A4 inducer, entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 77%, respectively. Coadministration of entrectinib with a moderate CYP450 3A4 inducer is predicted to decrease entrectinib Cmax and AUC by 43% and 56%, respectively. Reduced therapeutic efficacy may occur. MANAGEMENT: Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided. References "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.

Professional:

GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme. When a single 600 mg dose of entrectinib was administered with rifampin, a potent CYP450 3A4 inducer, entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 77%, respectively. Coadministration of entrectinib with a moderate CYP450 3A4 inducer is predicted to decrease entrectinib Cmax and AUC by 43% and 56%, respectively. Reduced therapeutic efficacy may occur.

MANAGEMENT: Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.

References
  • "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.
Entrectinib

Generic Name: entrectinib

Brand name: Rozlytrek

Synonyms: n.a.

Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction